CRISPR-Cas9 Based Gene Knock-out Method in Myeloid Cells
Register now to view on-demand
Targeted modification of a cell’s DNA via genome editing provides a powerful tool for fundamental biological research, early stage drug discovery, and for the development of novel cellular therapeutics, e.g. immunotherapy. The ability of CRISPR to introduce specific modifications into the genome allows tremendous flexibility in the choices of targets and assays and allows a precise determination of the drug target as part of functional genomics.
Join us and Dr. Heyne Cecilia Lee (AbbVie Deutschland GmbH & Co. KG, Neuroscience Discovery) at our free Webinar to learn about:
- The role of CRISPR in early drug discovery efforts, e.g. target validation
- How to generate Knock-outs in myeloid cells
- How to target microglial pathways for Alzheimer’s disease therapy
We look forward to welcoming you.
Your Lonza Bioscience Team
Speakers
Presenter:
Dr. Heyne Cecilia Lee
Dr. Heyne Cecilia Lee
Senior Scientist
AbbVie Deutschland GmbH & Co KG
AbbVie Deutschland GmbH & Co KG
Moderator:
Dr. Melanie Homberg
Market Development Manager
Lonza Bioscience
The user bears the sole responsibility for determining the existence of any third-party rights, as well as obtaining any necessary licenses, related to CRISPR-Cas 9 assays.
